177Lu-Lu-DOTA-TATE与标准治疗在成人胃肠胰神经内分泌肿瘤中的成本-后果分析:意大利医院视角
该成本-后果分析从意大利国家卫生服务体系视角,比较177Lu-Lu-DOTA-TATE、依维莫司(原研与仿制)和舒尼替尼在SSA治疗后进展的晚期GEP-NET(G1-G2)患者中的临床结局与成本。模型显示,在PanNET患者中每无进展月总成本177Lu-Lu-DOTA-TATE为2989欧元,低于原研依维莫司4975欧元、仿制依维莫司3472欧元和舒尼替尼5337欧元;在GI-NET患者中为3189欧元,低于原研依维莫司4990欧元和仿制依维莫司3483欧元。作者认为177Lu-Lu-DOTA-TATE虽获得与给药成本更高,但每无进展月成本更低。
要点
- 在PanNET患者中,每无进展月总成本177Lu-Lu-DOTA-TATE为2989欧元,低于原研依维莫司4975欧元、仿制依维莫司3472欧元和舒尼替尼5337欧元。
- 在GI-NET患者中,每无进展月总成本177Lu-Lu-DOTA-TATE为3189欧元,低于原研依维莫司4990欧元和仿制依维莫司3483欧元。
- 作者结论认为177Lu-Lu-DOTA-TATE虽然获得与给药成本更高,但每无进展月成本低于相关治疗选择。
核心结论
- 在SSA治疗后进展的GEP-NET(G1-G2)患者中,177Lu-Lu-DOTA-TATE每无进展月成本低于相关治疗选择,尽管其获得与给药成本更高。
- 这些发现为治疗决策提供了进一步的经济学论据。
研究设计与样本
- 成本-后果模型,由来自意大利三家NET参考中心的临床专家小组开发和验证。
- 比较177Lu-Lu-DOTA-TATE、依维莫司(原研和仿制)和舒尼替尼在晚期GEP-NET(G1和G2)且SSA治疗后进展患者中的疗效、安全性和成本。
- 临床结局包括中位无进展生存期和3级或4级不良事件发生率,取自关键临床试验报告。
- 成本和给药成本及不良事件管理成本从意大利国家卫生服务体系视角计算。
- 每无进展月治疗成本分别针对胰腺NET(PanNET,三种治疗)和胃肠NET(GI-NET,仅177Lu-Lu-DOTA-TATE和依维莫司)计算。
主要发现
- PanNET患者中,每无进展月总成本:177Lu-Lu-DOTA-TATE为2989欧元,原研依维莫司为4975欧元,仿制依维莫司为3472欧元,舒尼替尼为5337欧元。
- GI-NET患者中,每无进展月总成本:177Lu-Lu-DOTA-TATE为3189欧元,原研依维莫司为4990欧元,仿制依维莫司为3483欧元。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess and compare clinical outcomes and costs, to the Italian healthcare system, of three therapeutic options approved in the management of adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs). METHODS: We compared the efficacy, safety, and costs of [177Lu]Lu-DOTA-TATE, everolimus (both originator and generic products), and sunitinib in patients with advanced GEP-NETs (NET G1 and G2) that had progressed following treatment with somatostatin analogs (SSAs). A cost-consequence model was developed and validated by a panel of clinical experts from three NET reference centres in Italy. The clinical outcomes included in the model were median progression-free survival and the incidence of grade 3 or 4 adverse events (AEs), as reported in pivotal clinical trials. The costs for acquisition and administration of each treatment, and of managing AEs, were calculated from the perspective of the Italian national health service. Treatment costs per progression-free month were calculated separately for patients with NETs of pancreatic (PanNETs; all three treatments) and gastrointestinal (GI-NETs; [177Lu]Lu-DOTA-TATE and everolimus only) origin. RESULTS: In patients with PanNETs, total costs per progression-free month were €2989 for [177Lu]Lu-DOTA-TATE, €4975 for originator everolimus, €3472 for generic everolimus, and €5337 for sunitinib. In patients with GI-NETs, total costs per progression-free month were €3189 for [177Lu]Lu-DOTA-TATE, €4990 for originator everolimus, and €3483 for generic everolimus. CONCLUSIONS: [177Lu]Lu-DOTA-TATE was associated with lower costs per progression-free month versus relevant treatment options in patients with GI-NETs or PanNETs (NET G1-G2; progressed following SSA treatment), although acquisition and administration costs are higher. These findings provide further economic arguments in the overall context of treatment decision-making.
引用
- Spada F, Campana D, Lamberti G, et al. [177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective. Eur J Nucl Med Mol Imaging. 2021. PMID: 34950969. doi:10.1007/s00259-021-05656-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。